You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Prevalence, incidence and clinical features of neuromyelitis optica spectrum disorders in northern Japan
  1. Hideki Houzen1,
  2. Takahiro Kano1,
  3. Kimito Kondo2,
  4. Toshiyuki Takahashi3,
  5. Masaaki Niino4
  1. 1 Department of Neurology, Obihiro Kosei General Hospital, Obihiro, Japan
  2. 2 Departmentof Neurology, Hokuto Hospital, Obihiro, Hokkaido, Japan
  3. 3 Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
  4. 4 Department of Clinical Research, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan
  1. Correspondence to Dr Masaaki Niino, Department of Clinical Research, National Hospital Organization Hokkaido Medical Center, Sapporo 063-0005, Japan; niino.masaaki.tc{at}mail.hosp.go.jp

https://doi.org/10.1136/jnnp-2022-330274

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disorder of the central nervous system that predominantly targets the optic nerve and spinal cord. In 2001, we began conducting epidemiological surveys on multiple sclerosis (MS) and NMOSD in the Tokachi area of Hokkaido Island in Japan, and have since reported the data every 5 years. In the last survey in 2016, we first applied the 2015 criteria and reported that the prevalence of NMOSD in the Japanese population was similar to that in Caucasians.1 We conducted an epidemiological survey of NMOSD in 2021 to determine the prevalence and clinical characteristics of NMOSD in the Tokachi area, and to analyse its clinical characteristics. The population of Tokachi province per the Government Census Office was 334 736 (160 533 men, 174 203 women) at the end of March 2021. Processing sheets for the detailed coding of clinical data were sent to 14 MS-related and NMOSD-related institutions inside and outside this area, and were collected from April to May 2021. In this study, we used the NMOSD diagnostic criteria defined by the IPND in 2015.2 The Mann-Whitney U test or Kruskal-Wallis test was used to analyse differences in the clinical characteristics between groups.

    On the day the prevalence was determined (31 March 2021), 22 patients residing in the study area were diagnosed with NMOSD, which was …

    View Full Text

    Footnotes

    • Contributors HH: conception, design, analysis, interpretation of the data and preparation of the manuscript. TK and KK: acquisition of data. TT: measurement of anti-AQP4 antibody and anti-MOG antibody. MN: interpretation of the data, preparation of the manuscript and study supervision. All authors approved the final draft.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.